These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 20826931)

  • 1. Impacts of anti-EGFR monoclonal antibody in prostate cancer PC3 cells.
    Rezaiemanesh A; Majidi J; Baradaran B; Movasaghpour A; Nakhlband A; Barar J; Omidi Y
    Hum Antibodies; 2010; 19(2-3):63-70. PubMed ID: 20826931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
    Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
    J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
    Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
    Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
    Fan Z; Masui H; Altas I; Mendelsohn J
    Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection and characterization of an internalizing epidermal-growth-factor-receptor antibody.
    Zhao X; Dai W; Cao L; Zhu H; Yu Y; Ye Q; Wang M; Dai W; Lei P; Shen G
    Biotechnol Appl Biochem; 2007 Jan; 46(Pt 1):27-33. PubMed ID: 16886908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells.
    Bonner JA; Buchsbaum DJ; Rogers BE; Grizzle WE; Trummell HQ; Curiel DT; Fiveash JB; Ove R; Raisch KP
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):950-8. PubMed ID: 14967455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM
    Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Meenakshi A; Sivakumar N; Kumar RR; Shankar SG; Dean CJ; Modjtahedi H
    Hum Antibodies; 1999; 9(3):149-54. PubMed ID: 10690627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
    Chang C; Takayanagi A; Yoshida T; Shimizu N
    Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha.
    Fong CJ; Sherwood ER; Mendelsohn J; Lee C; Kozlowski JM
    Cancer Res; 1992 Nov; 52(21):5887-92. PubMed ID: 1394216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
    Zi X; Grasso AW; Kung HJ; Agarwal R
    Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide.
    Bianco C; Bianco R; Tortora G; Damiano V; Guerrieri P; Montemaggi P; Mendelsohn J; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2000 Nov; 6(11):4343-50. PubMed ID: 11106252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function.
    Zolfaghari A; Djakiew D
    Prostate; 1996 Apr; 28(4):232-8. PubMed ID: 8602399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
    Jia RP; Xu LW; Su Q; Zhao JH; Li WC; Wang F; Xu Z
    Asian J Androl; 2008 Sep; 10(5):758-64. PubMed ID: 18645679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
    Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
    Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells.
    Lee DH; Szczepanski MJ; Lee YJ
    J Cell Biochem; 2009 Apr; 106(6):1113-22. PubMed ID: 19229860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
    Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB
    Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
    Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
    Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.